BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Macquarie maintains outperform on Dr. Reddys Laboratories
Current valuation at around 17.5 times FY2017 estimated earnings per share is attractive. Acquisition to strengthen the domestic franchise of the company. Dermatology, Respiratory & Pediatrics are strong areas for the company.